共 50 条
- [1] Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP and AFEQT) in patients age 65 or older.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)Bordonaro, RobertoFrassineti, Giovanni LucaCiuffreda, LiberoAprile, GiuseppeThomas, AnneVishwanath, Raghu L.Zilocchi, ChiaraDochy, EmmanuelleTaieb, JulienSobrero, Alberto F.
- [2] Aflibercept in combination with FOLFIRI for the second-line treatment of patients with metastatic colorectal cancer: Interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP and AFEQT studies)EUROPEAN JOURNAL OF CANCER, 2013, 49 : S521 - S521Sobrero, A.Bordonaro, R.Frassineti, L.Di Bartolomeo, M.Thomas, A. L.Taieb, J.Lledo, G.Moore, Y.Zilocchi, C.Ferry, D. R.
- [3] Ziv-aflibercept in combination with FOLIRI for the second-line treatment of patients with metastatic colorectal cancer: Third interim safety data from the global aflibercept safety and quality-of-life program (ASQoP and AFEQT studies).JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)Bordonaro, RobertoSobrero, Alberto F.Iaffaioli, Rosario VincenzKroening, HendrikAlfonso, Pilar GarciaFrassineti, LucaCluffreda, LiberoMalello, EvaristoAprile, GiuseppeThomas, Anne L.Moore, YanZilocchi, ChiaraBrette, SandrineDochy, EmmanuelleLledo, GerardTaieb, Julien
- [4] Ziv-aflibercept in combination with FOLFIRI for 2nd-line treatment of patients with metastatic colorectal cancer: Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP/AFEQT) in patients age 65 and older.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Bordonaro, RobertoFrassineti, LucaCiuffreda, LiberoAprile, GiuseppeThomas, Anne L.Vishwanath, RaghuZilocchi, ChiaraDochy, EmmanuelleTaieb, JulienSobrero, Alberto F.
- [5] Ziv-aflibercept in combination with FOLFIRI for 2nd-line treatment of patients with metastatic colorectal cancer: Interim safety data from the global aflibercept safety and quality-of-life program (ASQoP/AFEQT) in patients pretreated with bevacizumab.JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Sobrero, Alberto F.Bordonaro, RobertoBencardino, KatiaPietrantonio, FilippoBauer, StefanTaieb, JulienGarreau-Laporte, PascaleZilocchi, ChiaraDochy, EmmanuelleLledo, Gerard
- [6] Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B).JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)Ferry, David RaymondSobrero, Alberto F.Bordonaro, RobertoSiena, SalvatorePietrantonio, FilippoBauer, StefanTaieb, JulienGarreau-Laporte, PascaleBrette, SandrineDochy, EmmanuelleLledo, Gerard
- [7] Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program in pts pretreated with bevacizumab (B).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)Sobrero, Alberto F.Bordonaro, RobertoBencardino, KatiaPietrantonio, FilippoBauer, StefanTaieb, JulienGarreau-Laporte, PascaleZilocchi, ChiaraDochy, EmmanuelleLledo, Gerard
- [8] Aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Safety and quality of life (QoL) data from the Spanish subgroup of the Aflibercept Safety and Quality-of-Life Program (ASQoP).JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)Rivera, FernandoMarques, Eduardo PoloAranda, EnriqueFernandez-Martos, CarlosMunoa, Adelaida La CastaGuillen, CarmenLopez, RafaelGil, SilviaLema, LauraAparicio, JorgeVillacampa, Mercedes MartinezPisa, AleydisBorrega, PabloLopez-Vivanco, GuillermoAlfonso, Pilar Garcia
- [9] Aflibercept plus FOLFIRI for treatment of metastatic colorectal cancer after oxaliplatin failure: 4th interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP/AFEQT studies)ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 106 - 107Kroening, H.Bauer, S.Frassineti, L.Di Bartolomeo, M.Thomas, A. L.Taieb, J.Lledo, G.Moore, Y.Zilocchi, C.Brette, S.Sobrero, A.Bordonaro, R.Heinemann, V
- [10] Aflibercept (afl) in combination with FOLFIRI for the 2nd-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety and quality-of-life (QoL) data from the Italian subgroup of the Aflibercept Safety and Quality-of-Life Program (ASQoP)EUROPEAN JOURNAL OF CANCER, 2013, 49 : S513 - S513Bordonaro, R.Passardi, A.Fasola, G.Ciuffreda, L.Di Bartolomeo, M.Siena, S.Di Costanzo, F.Fornarini, G.Cordio, S.Sobrero, A.